pravastatin has been researched along with Diabetic Nephropathies in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gad, HI | 2 |
| Arai, H; Minami, M; Murayama, T; Tamura, Y; Yokode, M | 1 |
| Inoguchi, T; Kimura, S; Maeda, Y; Sonoda, N; Takayanagi, R; Yokomizo, H | 1 |
| Bouchier-Hayes, D; Casey, RG; Chen, G; Joyce, M; Roche-Nagle, G | 1 |
| Craven, T; Curhan, G; Furberg, C; Isles, C; Keech, A; Packard, C; Pfeffer, M; Sacks, F; Shepherd, J; Simes, J; Tonelli, M; Tonkin, A; West, M | 1 |
| Coronado, M; Escola, JM; Robles, NR; Ruiz-Calero, R; Sánchez Casado, E | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Kurata, H; Murakawa, Y; Tajima, N; Utsunomiya, K; Yokota, T | 1 |
| Davies, JE; Ng, LL | 1 |
| Kawagishi, T; Morii, H; Nishizawa, Y; Okuno, Y; Shoji, T; Toyokawa, A | 1 |
1 review(s) available for pravastatin and Diabetic Nephropathies
| Article | Year |
|---|---|
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
2 trial(s) available for pravastatin and Diabetic Nephropathies
| Article | Year |
|---|---|
Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy.
Topics: Aged; Albuminuria; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Male; Pravastatin; Quinolines; Treatment Outcome | 2012 |
Effect of pravastatin in people with diabetes and chronic kidney disease.
Topics: Adult; Age Distribution; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prevalence; Probability; Prognosis; Renal Insufficiency, Chronic; Risk Assessment; Sex Distribution; Treatment Outcome | 2005 |
9 other study(ies) available for pravastatin and Diabetic Nephropathies
| Article | Year |
|---|---|
Does combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy?
Topics: Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycated Hemoglobin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Kidney; Lipid Peroxides; Peroxisome Proliferator-Activated Receptors; Pravastatin; Rats; Rosiglitazone; Thiazolidinediones; Transferrin; Tumor Necrosis Factor-alpha | 2014 |
Differential effect of statins on diabetic nephropathy in db/db mice.
Topics: Adiposity; Albuminuria; Animals; Blood Pressure; Body Weight; Creatinine; Diabetic Nephropathies; Fluorobenzenes; Insulin Resistance; Male; Mice; Oxidative Stress; Pravastatin; Pyrimidines; Quinolines; Real-Time Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides | 2011 |
Effects of pravastatin or 12/15 lipoxygenase pathway inhibitors on indices of diabetic nephropathy in an experimental model of diabetic renal disease.
Topics: Albuminuria; Animals; Anticholesteremic Agents; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Kidney; Male; Oxidative Stress; Pravastatin; Rats; Rats, Wistar; Signal Transduction; Treatment Outcome | 2012 |
Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Glomerular Filtration Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pravastatin; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Circulation; Renal Insufficiency; Triglycerides; Urine | 2005 |
[Treatment with pravastatin of dyslipidemia associated with diabetic nephropathy].
Topics: Anticholesteremic Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin | 1998 |
Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Cultured; Diabetic Nephropathies; Gene Expression; Genes, ras; Glomerular Mesangium; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Rats; Rats, Wistar; RNA, Messenger; Transforming Growth Factor beta | 1999 |
Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Markov Chains; Middle Aged; Pravastatin; Quality-Adjusted Life Years; Sulfonylurea Compounds; United States | 2002 |
Lipids and cellular Na+/H+ antiport activity in diabetic nephropathy.
Topics: Carrier Proteins; Diabetic Nephropathies; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Membranes; Leukocytes; Lipids; Lipoproteins; Pravastatin; Reference Values; Sodium-Hydrogen Exchangers | 1992 |
Decreased albuminuria by pravastatin in hyperlipidemic diabetics.
Topics: Aged; Albuminuria; Diabetic Nephropathies; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin | 1991 |